You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
君實生物-B(01877.HK)治療膀胱癌新藥上市申請獲國家藥監局受理
阿思達克 05-08 09:30
君實生物-B(01877.HK)公布,公司與子公司蘇州眾合生物醫藥科技近日收到國家藥監局簽發的特瑞普利單抗注射液用於治療既往接受過系統治療的局部進展或轉移性尿路上皮癌的新適應症上市申請的《受理通知書》。

尿路上皮癌是目前最常見的膀胱癌類型。在中國,標準化療失敗的晚期尿路上皮癌患者治療手段非常有限,特瑞普利單抗注射液的註冊申報將為廣大患者提供更好的藥物治療選擇。公司將按國家有關法規積極推進上述研發項目,並及時對項目後續進展情況履行信息披露義務。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account